Literature DB >> 761385

Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.

N Christophidis, G Mihaly, F Vajda, W Louis.   

Abstract

A liquid-chromatographic assay of 5-fluorouracil in plasma is described. Advantages of this procedure over gas chromatography are the simpler extraction procedure, elimination of the need for a derivitization step with silylating agents, and a 20-fold greater sensitivity. The minimum detectable concentration of 5-fluorouracil in plasma is 25 microgram/L. The enhanced sensitivity enabled measurement of the concentrations of 5-fluorouracil found in plasms of patients receiving continuous intravenous infusions of the drug; such concentrations are generally unmeasurable by gas-chromatographic methods. We compared liquid-chromatographic and gas-chromatographic measurements on 36 plasma samples obtained from patients after rapid intravenous injection of 5-fluorouracil. The resulting correlation coefficient was 0.97, with a regression slope of 0.94. The liquid-chromatographic method is free of interference from other cytotoxic agents, anti-emetics, and folate derivatives that are frequently combined with 5-fluorouracil therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761385

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

1.  A simple high pressure liquid chromatographic method for the determination of fluorouracil to monitor patients on regional infusion for hepatic metastases.

Authors:  C H Koks; H J Van der Kam; J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

2.  Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

Authors:  Francis Lévi; Abdoulaye Karaboué; Marie-Christine Etienne-Grimaldi; Gilles Paintaud; Christian Focan; Pasquale Innominato; Mohamed Bouchahda; Gérard Milano; Etienne Chatelut
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Salivary passage of 5-fluorouracil during continuous infusion.

Authors:  G Milano; A Thyss; J Santini; M Frenay; E Francois; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

5.  Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.

Authors:  S Stremetzne; M Streit; E D Kreuser; W Schunack; U Jaehde
Journal:  Pharm World Sci       Date:  1999-08

6.  Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.

Authors:  A Thyss; G Milano; N Renée; J Vallicioni; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva.

Authors:  L A Celio; G J DiGregorio; E Ruch; J Pace; A J Piraino
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.

Authors:  P M Loadman; M C Bibby; J A Double; R S McElhinney
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

9.  Microdialysis sampling for the investigation of dermal drug transport.

Authors:  J M Ault; C E Lunte; N M Meltzer; C M Riley
Journal:  Pharm Res       Date:  1992-10       Impact factor: 4.200

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.